Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Wells Fargo Reiterates Overweight Rating on Autolus Therapeutics plc (AUTL)
May 20, 2024 6:43 AM EDTWells Fargo analyst Yanan Zhu reiterated an Overweight rating and $8.00 price target on Autolus Therapeutics plc (NASDAQ: AUTL).
The analyst comments "We continue to see AUTL as well positioned for upside on 2H24 catalysts incl. B-ALL PDUFA (11/16) and first SLE data (late... More
